HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 25, No. 07, July 2021 – Ageing Better – Breakthroughs and Innovations for a Greying World       » A Plant-Based Remedy for Big, Broken Hearts       » Fuelling the Future with Multi-Element Alloys and Green Hydrogen       » RADICA: A Radical, Rapid Method for Accurate Detection of Viruses       » Untangling the Twists of Alzheimer’s Plaques       » Turning Aquaculture Trash to Treasure for Tissue Repair      
NEWS CRUNCH
Zika Virus Urgently Needs Improved Detection Methods as Vaccine Development Faces Array of Obstacles, says GlobalData Analyst
LONDON, UK (GlobalData), 16 February 2016 - The growing threat of the Zika virus, which the World Health Organization believes could infect four million people in the Americas over the next twelve months, must be addressed using a multi-pronged approach, according to an analyst with research and consulting firm GlobalData.

Mirco Junker, Ph.D., GlobalData's Analyst covering Infectious Diseases, says that while a vaccine could be an effective measure in the long term, it remains several years away and faces numerous obstacles to development. As such, limiting people's contact with mosquitoes and developing effective diagnostic tests are more crucial short-term measures.

Junker explains: "The first step in fighting the Zika virus is to address the vector responsible for its transferral to humans - mosquitoes. Achievable actions, such as eliminating shallow standing water, using insecticides, and implementing next-generation genetic or microbiological approaches, would all contribute to the reduction of Zika vector populations.

"Furthermore, the development of a reliable and cost-effective method to detect Zika infections is of paramount importance. The test would need to be sensitive and specific, with high cost-effectiveness, so that it may be employed on a large scale and be able to detect the large proportion of disease cases which are asymptomatic."

The analyst adds that while an effective long-term solution would be a vaccine that offers strong and durable protection against Zika, this could take years to become a reality.

Junker continues: "Several companies, including GlaxoSmithKline, Merck, Johnson & Johnson, Pfizer, and Sanofi, have already expressed interest in developing a Zika virus vaccine, but the current lack of scientific data on Zika presents a major barrier.

"The development of Sanofi's vaccine for dengue, a disease carried by the same type of mosquito as Zika, has taken 20 years, and its efficacy in certain patient populations, most notably flavivirus-na?ve individuals, has still not been definitively proven.

"Therefore, even though the Zika virus has been sequenced, it is currently not clear what the best approach in developing a Zika virus vaccine will be, and a definitive timeline on vaccine development is impossible to ascertain."

Source: GlobalData
NEWS CRUNCH  
news Singapore Health & Biomedical Congress 2021 is Set to Brave the New Frontiers as We Revolutionise and Transform Healthcare
news Anti-Pandemic Forum to be Hosted by Top-Notch American and Chinese Scientists
news Commemorating World Health Day with Viatris
news Entire industrial chain resources of advanced medical equipment are lining up at Medtec China 2021
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy